#1 Startup Dataset
Growth rates, revenue data, direct competitors and contact details.
Steve Kradjian Email
VP, Regulatory and Quality . ViaCyte
How to contact Steve Kradjian
Join and see Steve's contact info for free!Current Roles
Employees:
56Revenue:
$4.3MAbout
ViaCyte is a privately-held regenerative medicine company developing novel cell replacement therapies as potential long-term diabetes treatments that will reduce or eliminate the need for blood glucose monitoring, insulin administration, and the risks of hypoglycemia and diabetes-related complications. ViaCyte has two products in clinical development. The first is called the PEC-Direct product candidate, which delivers proprietary pancreatic progenitor cells (PEC-01 cells) in a non-immunoprotective device. The PEC-Direct product candidate is being developed for type 1 diabetes (T1D) patients who have hypoglycemia unawareness, recurrent severe hypoglycemic episodes, and/or extreme glycemic lability. The second product is called the PEC-Encap (also known as VC-01) product candidate. The PEC-Encap product candidate delivers pancreatic progenitor cells in an immunoprotective device and is being developed as a potential therapy for all diabetes patients who use insulin to control their disease. www.viacyte.comViaCyte Address
3550 General Atomics CourtSan Diego, CA
United States